共 74 条
[1]
Kleijnen S(2015)Can a joint assessment provide relevant information for national/local relative effectiveness assessments? an in-depth comparison of pazopanib assessments Value Health. 18 663-672
[2]
Fathallah M(2012)Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions Value Health. 15 954-960
[3]
van der Linden MW(2017)A comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment? Front Pharmacol. 8 384-951
[4]
Vancraeynest P(2020)Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): a first step towards a consolidated European perspective on comparative effectiveness & safety? Health Policy 124 943-76
[5]
Dahmani B(2017)Variation in health technology assessment and reimbursement processes in Europe Value Health. 20 67-8
[6]
Timoney A(2009)Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA Int J Technol Assess Health Care. 25 1-116
[7]
Kleijnen S(2009)European network for health technology assessment, EUnetHTA: planning, development, and implementation of a sustainable European network for health technology assessment Int J Technol Assess Health Care. 25 107-477
[8]
George E(2014)Eunethta: further steps towards European cooperation on health technology assessment Int J Technol Assess Health Care. 30 475-10
[9]
Goulden S(2018)The future of European cooperation on health technology assessment Eurohealth. 24 7-653
[10]
d'Andon A(2017)Evaluation of the Hta core model for national health technology assessment reports: comparative study and experiences from European Countries Int J Technol Assess Health Care. 33 644-1186